Home / Health / Cancer Drug Shortage Cripples India's Treatment Plans
Cancer Drug Shortage Cripples India's Treatment Plans
5 Jun
Summary
- Critical chemotherapy drugs Cisplatin and Carboplatin are in short supply across India.
- Hospitals report dwindling stocks, forcing patients to search for the drugs themselves.
- Rising input costs are cited as the primary reason for the prolonged shortage.
Cancer patients across India are in a critical situation due to a severe shortage of essential chemotherapy drugs, Cisplatin and Carboplatin. Hospitals nationwide are reporting drastically dwindling supplies, with some having only a few days' worth of medication left.
This scarcity is forcing patients and their families to actively search for pharmacies and distributors to procure these vital drugs themselves. The absence of Cisplatin and Carboplatin, used in treating numerous common cancers, poses a significant threat to treatment continuity and can negatively affect survival and recurrence rates.
The prolonged shortage, which has persisted for about 40 days, is primarily attributed to escalating input costs for these platinum-based medications. Manufacturers have indicated that current price-controlled rates are insufficient to cover the increased expenses of imported components, leading some to reduce or halt production.
Industry representatives suggest that while some manufacturers have reduced production, there are concerns that some may continue exporting the drugs, further constraining domestic supplies. Efforts to secure a price revision for these essential medicines are reportedly underway but remain under consideration, leaving patients in a precarious situation.
